Page 95 - 南京医科大学自然版

第44卷第4期 喻 悦，王瑜亮，张 晓. 葡萄糖代谢重编程在胰腺癌耐药中的研究进展［J］.
2024年4月 南京医科大学学报（自然科学版），2024，44（04）：524-535，572 ·533 ·

［14］ZHONG X Y，HE X F，WANG Y X，et al. Warburg effect ［26］PERUSINA L M，THOMPSON J K，BEDNAR F，et al. Me⁃
in colorectal cancer：the emerging roles in tumor microen⁃ tabolism and epigenetics of pancreatic cancer stem cells［J］.
vironment and therapeutic implications［J］. J Hematol On⁃ Semin Cancer Biol，2019，57：19-26
col，2022，15（1）：160 ［27］LIU K，JIN H W，ZHOU B. Genetic lineage tracing with
［15］CAO L L，WANG M，DONG Y J，et al. Circular RNA multiple DNA recombinases：a user’s guide for conduct⁃
circRNF20 promotes breast cancer tumorigenesis and ing more precise cell fate mapping studies［J］. J Biol
Warburg effect through miR⁃487a/HIF⁃1α/HK2［J］. Cell Chem，2020，295（19）：6413-6424
Death Dis，2020，11（2）：145 ［28］MARTÍNEZ ⁃ CHANTAR M L，VÁZQUEZ ⁃ CHANTADA
［16］POFF A，KOUTNIK A P，EGAN K M，et al. Targeting the M，ARIZ U，et al. Loss of the glycine N⁃methyltransferase
Warburg effect for cancer treatment：ketogenic diets for gene leads to steatosis and hepatocellular carcinoma in
management of glioma［J］. Semin Cancer Biol，2019，56： mice［J］. Hepatology，2008，47（4）：1191-1199
135-148 ［29］MEIDHOF S，BRABLETZ S，LEHMANN W，et al. ZEB1⁃
［17］VAUPEL P ，MULTHOFF G. Revisiting the Warburg associated drug resistance in cancer cells is reversed by
effect：historical dogma current understanding［J］. J the class I HDAC inhibitor mocetinostat［J］. EMBO Mol
Physiol⁃London，2021，599（6）：1745-1757 Med，2015，7（6）：831-847
［18］FUKAHORI M，OKABE Y，SHIMOKAWA M，et al. Effi⁃ ［30］WEI L，SUN J J，WANG X W，et al. Noncoding RNAs：an
cacy of second ⁃ line chemotherapy after treatment with emerging modulator of drug resistance in pancreatic can⁃
gemcitabine plus nab⁃paclitaxel or FOLFIRINOX in pa⁃ cer［J］. Front Cell Dev Biol，2023，11：1226639
tients with metastatic pancreatic cancer［J］. Sci Rep， ［31］HAMADA S，MASAMUNE A，MIURA S，et al. MiR⁃365
2023，13（1）：19399 induces gemcitabine resistance in pancreatic cancer cells
［19］CHEN X，ZHENG P C，XUE Z F，et al. CacyBP/SIP en⁃ by targeting the adaptor protein SHC1 and pro⁃apoptotic
hances multidrug resistance of pancreatic cancer cells by regulator BAX［J］. Cell Signal，2014，26（2）：179-185
regulation of P⁃gp and Bcl⁃2［J］. Apoptosis，2013，18（7）： ［32］WANG P，ZHUANG L P，ZHANG J，et al. The serum miR⁃
861-869 21 level serves as a predictor for the chemosensitivity of
［20］BUKOWSKI K，KCIUK M，KONTEK R. Mechanisms of advanced pancreatic cancer，and miR⁃21 expression con⁃
multidrug resistance in cancer chemotherapy［J］. Int J fers chemoresistance by targeting FasL［J］. Mol Oncol，
Mol Sci，2020，21（9）：3233 2013，7（3）：334-345
［21］QI R，BAI Y X，LI K，et al. Cancer⁃associated fibroblasts ［33］ZHOU C F，YI C H，YI Y X，et al. LncRNA PVT1 pro⁃
suppress ferroptosis and induce gemcitabine resistance in motes gemcitabine resistance of pancreatic cancer via ac⁃
pancreatic cancer cells by secreting exosome ⁃ derived tivating Wnt/β ⁃ catenin and autophagy pathway through
ACSL4⁃targeting miRNAs［J］. Drug Resist Updat，2023， modulating the miR ⁃ 619 ⁃ 5p/Pygo2 and miR ⁃ 619 ⁃ 5p/
68：100960 ATG14 axes［J］. Mol Cancer，2020，19（1）：118
［22］KASHYAP V K，WANG Q H，SETUA S，et al. Therapeu⁃ ［34］NALLASAMY P，NIMMAKAYALA R K，KARMAKAR S，
tic efficacy of a novel βIII/βIV⁃tubulin inhibitor（VERU⁃ et al. Pancreatic tumor microenvironment factor promotes
111）in pancreatic cancer［J］. J Exp Clin Cancer Res， cancer stemness via SPP1⁃CD44 axis［J］. Gastroenterology，
2019，38（1）：29 2021，161（6）：1998-2013
［23］GOLAN T，RAITSES⁃GUREVICH M，BELLER T，et al. ［35］ASHRAFIZADEH M，LUO K，ZHANG W，et al. Acquired
Strategies for the management of patients with pancreatic and intrinsic gemcitabine resistance in pancreatic cancer
cancer with PARP inhibitors［J］. Cancer Treat Res，2023， therapy：environmental factors，molecular profile and
186：125-142 drug/nanotherapeutic approaches［J］. Environ Res，2024，
［24］ZHAO H Q，DUAN Q K，ZHANG Z L，et al. Up⁃regula⁃ 240（Pt 2）：117443
tion of glycolysis promotes the stemness and EMT pheno⁃ ［36］QIU J D，FENG M Y，YANG G，et al. mTOR inhibitor，
types in gemcitabine⁃resistant pancreatic cancer cells［J］. gemcitabine and PD ⁃ L1 antibody blockade combination
J Cell Mol Med，2017，21（9）：2055-2067 therapy suppresses pancreatic cancer progression via meta⁃
［25］WANG Z W，PAN J J，HU J F，et al. SRSF3⁃mediated regu⁃ bolic reprogramming and immune microenvironment re⁃
flox/+ G12D/+
lation of N6⁃methyladenosine modification⁃related ln⁃ modeling in Trp53 LSL ⁃ Kras Pdx ⁃ 1 ⁃ Cre murine
cRNA ANRIL splicing promotes resistance of pancreatic models［J］. Cancer Lett，2023，554：216020
cancer to gemcitabine［J］. Cell Rep，2022，39（6）：110813 ［37］YUN H J ，LI M，GUO D，et al. AMPK⁃HIF⁃1α signaling